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Trends in EGFR Gene Mutations and Responses to Treatment of Advanced
Recurrent Non-Small Cell Lung Carcinoma at Tokushima Red Cross Hospital
Hisashi ISHIKURA１）, Daisuke MATSUMOTO２）, Suguru KIMURA１）,
Yuki KUMIHASHI３）, Yukari FUKUSHIMA３）
１）Division of Surgery, Tokushima Red Cross Hospital
２）Division of Respiratory Surgery, Tokushima University
３）Division of Pharmacy, Tokushima Red Cross Hospital
［Introduction］Trends in gene mutations and responses of each mutation type to treatment were analyzed at
our department.［Methods］Of the samples collected from１１２ cases until October２０１４,４３ were EGFR gene mu-
tation positive. Mutations were noted in Exon１９（３８．３％）, Exon２１（３１．９％）, Exon１８（１９．１％）, Exon２０（１０．６％）,
and multiple exons in some cases, with about７０％ of all mutations being found in Exon１９ or２１. The nature
and duration of treatment and the survival period were analyzed in cases with known treatment courses, ex-
cluding those left untreated.［Results］On the basis of the expectation that the duration of use would be longer
for the drugs manifesting efficacy, the ratio of the duration of EGFR-TKI treatment（１ month ＝１ unit）to the
duration of chemotherapy（１ course ＝ １ unit）was calculated. This ratio was ２：１ for the Exon １９ mutation
group and１：１ for the Exon２１ and Exon２０ mutation groups. Patients with Exon １８ mutations were mostly
treated with chemotherapy alone. The median survival period was２８ months for patients with Exon１９ muta-
tions（range：４－４２ months,６ cases alive）,２０ months（６－７０,３ cases alive）for patients with Exon２１ muta-
tions,５months（５－４９,１ case alive) for patients with Exon１８mutations, and１４months（１３－１５,１ case alive）
for patients with Exon２０ mutations.［Discussion］Patients with Exon１９ mutations survived for approximately３０
months with high reliability. Survival longer than５ years was possible in some cases with Exon２１ mutations,
although treatment efficacy varied among individual cases and the percentage of anti-cancer drug treated cases
was higher. Cases with Exon１８ mutations responded poorly to EGFR-TKI and cases with Exon２０ mutations
survived for only one year. These results indicate the necessity of devising therapeutic strategies tailored to the
type of gene mutation.
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